GlassScriptPhysician profile
Barbara J Verga
NPI 1952364358
$1,095.75
in general payments reported to CMS, 2019-2025
12 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2020: $43.69 · 2021: $201 · 2022: $97.52 · 2023: $141 · 2024: $212 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642 · Education: $14.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.79 |
| Education | $14.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.84 | 2019-2025 | |
| Genzyme Corporation | $155.23 | 2023-2025 | |
| Janssen Biotech, INC. | $121.29 | 2019-2024 | Stelara, Tremfya |
| Qol Medical, LLC | $93.18 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $71.49 | 2023-2024 | Dupixent |
| Coloplast Corp | $34.78 | 2024-2025 | |
| Celltrion USA INC. | $33.65 | 2024-2025 | Vegzelma, Zymfentra |
| Sandoz INC. | $21.84 | 2023 | Hyrimoz |
| Sanofi US Services INC. | $21.19 | 2025 | |
| Travere Therapeutics, INC. | $18.62 | 2023 | Cholbam |
| Fresenius Kabi USA, LLC | $14.64 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Verga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.